Drug Profile
MEDI 1191
Alternative Names: MEDI-1191Latest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class Antineoplastics; Immunotherapies; Lipids; RNA
- Mechanism of Action Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 Aug 2023 Medimmune completes a phase I trials in Solid tumours (Monotherapy, Combination therapy, In adults, In the elderly, Second-line therapy or greater, Late-stage disease) in USA and Spain (Intratumoural) (NCT03946800)
- 14 Apr 2023 Efficacy, adverse events and pharmacodynamics data from a phase I trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 22 Sep 2022 MEDI 1191 is still in phase I trials for Solid-tumours in the USA (NCT03946800)